SparingVision
Clinical-stage biotechnology company developing genomic medicines for inherited retinal diseases. Focus areas include mutation-independent (gene-agnostic) gene therapies, genome editing collaborations, and in vivo reprogramming. The company advances programs from discovery through nonclinical development and clinical trials, with dedicated CMC, regulatory, clinical and logistics capabilities for ocular gene therapies.
Industries
Nr. of Employees
small (1-50)
SparingVision
Paris, Ile-de-France, France, Europe
Products
SPVN06
Lead AAV-based gene therapy program intended to preserve cone photoreceptors by delivering neurotrophic and antioxidant transgenes (RdCVF and RdCVFL isoforms) to retinal cells via subretinal administration. Designed as a mutation-independent therapy for inherited retinal diseases and geographic atrophy secondary to dry AMD. Currently in Phase I/II clinical development.
SPVN20
Gene-agnostic program designed to introduce an alternative phototransduction mechanism to reactivate dormant cone photoreceptors, with the objective of restoring visual acuity and color vision in advanced retinal degeneration independently of causative mutation.
SPVN06
Lead AAV-based gene therapy program intended to preserve cone photoreceptors by delivering neurotrophic and antioxidant transgenes (RdCVF and RdCVFL isoforms) to retinal cells via subretinal administration. Designed as a mutation-independent therapy for inherited retinal diseases and geographic atrophy secondary to dry AMD. Currently in Phase I/II clinical development.
SPVN20
Gene-agnostic program designed to introduce an alternative phototransduction mechanism to reactivate dormant cone photoreceptors, with the objective of restoring visual acuity and color vision in advanced retinal degeneration independently of causative mutation.
Expertise Areas
- Clinical trial management (ophthalmology)
- Gene therapy development for retinal diseases
- Mutation-independent therapeutic strategies
- Genome editing collaborations (CRISPR-based)
Key Technologies
- AAV gene delivery
- Mutation-independent (gene-agnostic) gene therapy approaches
- CRISPR-based genome editing
- In vivo cellular reprogramming techniques